by George Ciuciureanu | Apr 24, 2025 | Events, Health
Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA). Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of...
by George Ciuciureanu | Apr 22, 2025 | Health, News
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing...
by George Ciuciureanu | Apr 16, 2025 | Health, News
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune...
by George Ciuciureanu | Apr 15, 2025 | Events, Health
Vancouver, Canada – April 15, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that multiple scientific abstracts have been accepted for presentation at major international rheumatology and diagnostics conferences...
by George Ciuciureanu | Apr 1, 2025 | Health, News
Augurex is featured in a RheumNow Therapeutic Update with Dr. Walter Maksymowych, highlighting the role of 14-3-3eta across the RA care continuum. In this feature, Dr. Walter Maksymowych explores how 14-3-3eta helps close diagnostic and monitoring gaps in RA care....
by George Ciuciureanu | Mar 10, 2025 | Health, News
Augurex has received UK Conformity Assessed marking for JOINTstat®, authorizing its use in Great Britain for rheumatoid arthritis diagnosis and management. JOINTstat® is a well-established rheumatoid arthritis blood test in North America, approved by Health Canada and...
